El interés en corto de International Seaways da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de International Seaways. Los datos de interés en corto se actualizan cada dos semanas.

International Seaways (NYSE:INSW) Bolsa, Informe de interés en corto

International Seaways

International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.

International Seaways Inc

WIIM

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health shares are trading lower after Novo Nordisk reportedly terminated its collaboration with the company.

CARM

OCGN

Carisma Therapeutics And Ocugen Subsidiary, OrthoCellix, Enter All-Stock Merger Agreement; Carisma Will Issue To The Pre-Merger OrthoCellix Stockholder Shares Of Carisma Common Stock As Merger Consideration In Exchange For The Cancellation Of Shares Of Capital Stock Of OrthoCellix

Fractyl Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced positive 3-month data from the REVEAL-1 Cohort of its ongoing REMAIN-1 pivotal study. These findings suggest Revita may help people stay at their target weight or lose additional weight, even after discontinuing GLP-1 drugs, offering a potential path to durable, drug-free weight maintenance.
3-Month Outcomes in REVEAL-1 Show Strong Early Signal for Durable Weight Maintenance REVEAL-1 is the open-label cohort within the ongoing REMAIN-1 pivotal study, designed to evaluate the safety, tolerability, and early efficacy signals of Revita in individuals with obesity who have lost at least 15% of their total body weight on a recently discontinued GLP-1 therapy. This cohort serves as an early clinical window into Revita's potential to support durable weight maintenance following GLP-1 discontinuation, a period of time when patients are typically vulnerable to rapid weight regain. Participants undergo a single Revita procedure in an open-label setting and receive structured diet and lifestyle support consistent with the ongoing randomized, controlled, REMAIN-1 clinical study. The insights from REVEAL-1 are intended to inform and complement data from the randomized Midpoint and Pivotal Cohorts in REMAIN-1.
To date, 22 participants have been treated in the REVEAL-1 Cohort, with 3-month follow-up data available for 13 individuals. The profile of the REVEAL-1 Cohort closely mirrors that of the REMAIN-1 Midpoint and Pivotal Cohorts, with an average age of 49 and a gender distribution of 11 women and 2 men. All participants had previously been treated with a GLP-1 therapy for durations ranging from approximately 5 months to 3 years, with a median total body weight (TBW) loss of 20.9% while on therapy. Fifteen percent of participants had pre-diabetes at baseline.
<ul>
<li>At 3 months, 12 of 13 participants either lost or maintained their weight after GLP-1 discontinuation and a single Revita procedure. Notably, 6 of 13 experienced further weight loss.</li>
<li>Median weight remained stable through 3 months (TBW change of 0.46% / ~ 1 pound was within the margin of error for daily weight measurement), compared to the typical 5-6% (10–15 pounds) rebound seen in clinical studies such as SURMOUNT-41 2. Only one participant experienced weight regain similar to that seen after tirzepatide withdrawal.</li>
<li>Early signs also point to excellent weight stability following Revita procedure, with essentially no weight change between 1 and 3 months (median weight gain at 1 month: 0.43% and 3 months: 0.46%).</li>
<li>Consistent with prior studies of Revita, the procedure was well tolerated, with no unanticipated or serious adverse effects. No new safety concerns were observed.</li>
</ul>

News

GUTS

Fractyl Reports Most Patients Maintained or Lost Weight 3 Months After Stopping GLP-1 Drugs

Health Care

General

Novo Nordisk Terminates Collaboration With Hims & Hers Health, Direct Access To Wegovy Will No Longer Be Available To Hims & Hers Health, Inc. Via Novocare Pharmacy

JP Morgan analyst Daniel Politzer initiates coverage on Park Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>) with a Underweight rating and announces Price Target of $10.

Price Target

Initiation

Analyst Ratings

JP Morgan Initiates Coverage On Park Hotels & Resorts with Underweight Rating, Announces Price Target of $10

Baird analyst David Tarantino maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Neutral and raises the price target from $218 to $230.

Baird Maintains Neutral on Darden Restaurants, Raises Price Target to $230

<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="896" height="504" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23064915/Syringes.jpg" alt="" class="wp-image-14732" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23064915/Syringes.jpg 896w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23064915/Syringes-300x169.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23064915/Syringes-768x432.jpg 768w" sizes="(max-width: 896px) 100vw, 896px" /></figure>
Two Biotechs Poised For Big Moves On Monday (Sana Biotechnology &#x7C; Lineage Cell Therapeutics)
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">1&#xFE0F;&#x20E3; Sana Biotechnology</h3>
Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>)
Catalyst: Invited six-month clinical update — ADA Scientific Sessions, Monday @ 10:30 a.m. CT <a href="https://ir.sana.com/news-releases/news-release-details/sana-biotechnology-announces-invited-oral-presentation-85th?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">ir.sana.com</a><a href="https://www.globenewswire.com/news-release/2025/06/09/3096183/0/en/Sana-Biotechnology-Announces-Invited-Oral-Presentation-at-the-85th-Annual-American-Diabetes-Association-Scientific-Sessions.html?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">globenewswire.com</a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>What we'll hear</th>
<th>Why it matters</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-in-human data on UP421, a hypoimmune‐modified islet-cell therapy for Type 1 diabetes</td>
<td>• One treated patient is six months insulin- &amp; immunosuppression-free. • If replicated, UP421 could leapfrog donor-islet transplants, the current gold standard that still requires lifelong immunosuppression.</td>
</tr>
<tr>
<td>Safety &amp; durability profile through 180 days</td>
<td>• The ADA crowd is data‐driven: low adverse events and durable C-peptide levels would de-risk the platform.</td>
</tr>
<tr>
<td>Expansion path (multi-patient cohort)</td>
<td>• Positive signals open the door to "breakthrough" or RMAT dialogue with FDA, accelerating timelines.</td>
</tr>
</tbody>
</table>
</figure>
Why the stock could pop Monday
<ul class="wp-block-list">
<li>Audience effect: the ADA meeting pulls in ~11-12 k registrants; roughly 3–4 k are adult endocrinologists who influence treatment paradigms and often trade or recommend names they've just seen. <a href="https://www.breakthrought1d.org/news-and-updates/adas-85th-scientific-sessions/?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">breakthrought1d.org</a></li>
<li>Scarcity value: no other public company has shown insulin independence without immunosuppression.</li>
<li>Float dynamics: SANA's free float is only ~24 % of shares outstanding; a modest uptick in buy-interest can move the tape quickly.</li>
</ul>
Watch-for: If the single-patient success extends to the next two patients in cohort B, look for sell-side upgrades and chatter about a pivotal trial design in H2-25.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">2&#xFE0F;&#x20E3; Lineage Cell Therapeutics</h3>
Lineage Cell Therapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#NYSE">LCTX</a>)
Catalyst window: Genentech PR "within weeks" + 36-month OpRegen&#xAE; read-out at CTS-2025 (June 27) <a href="https://www.businesswire.com/news/home/20250512395886/en/RG6501-OpRegen-Phase-12a-Clinical-Study-36-Month-Results-to-Be-Featured-at-Clinical-Trials-at-the-Summit-2025?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">businesswire.com</a><a href="https://www.businesswire.com/news/home/20250605204221/en/Lineage-Cell-Therapeutics-Announces-Updates-to-the-3rd-Annual-Spinal-Cord-Injury-Investor-Symposium?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">businesswire.com</a><a href="https://www.modernretina.com/view/lineage-to-announce-data-from-phase-1-2a-study-on-use-of-rg6501?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">modernretina.com</a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>What could hit</th>
<th>Price-sensitive angle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roche Holding AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) subsidiary Genentech/LCTX services-agreement milestones or data-share PR</td>
<td>• Prior Genentech press releases on OpRegen have triggered double-digit one-day moves in LCTX.</td>
</tr>
<tr>
<td>36-month functional vision data (phase 2a, GA secondary to AMD)</td>
<td>• If BCVA gains remain ≥7 letters and lesion growth stays slowed, analysts will start modelling blockbuster-size royalties.</td>
</tr>
<tr>
<td>Potential partner opt-in for spinal cord (SCIIS meeting)</td>
<td>• Separately, Lineage tees-up a June 27 investor symposium on spinal cord injury – any strategic partner news adds another risk-on spark.</td>
</tr>
</tbody>
</table>
</figure>
Why Monday could be the start of a new leg
<ul class="wp-block-list">
<li>Pattern set-up: the stock has been basing in the $1.60–1.80 zone; traders remember the May 2024 Genentech PR that drove a 40 % gap.</li>
<li>Valuation gap: LCTX trades at &lt; 3× 2026e OpRegen royalty sales versus cell-therapy peers at 8–10×.</li>
<li>Short-term IV low: front-month at-the-money calls imply a ±12 % move by July — well under the 20–30 % jumps we saw on the last three data bursts.</li>
</ul>
Watch-for: A Monday-morning 8-K or Genentech newsroom post; if nothing drops, option premiums may leak until later in the week — keep a trading tranche nimble.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Tactical takeaways</h3>
<ol class="wp-block-list">
<li>SANA: momentum play into the ADA deck. Small float + novel cure angle = potential volatility.</li>
<li>LCTX: event-driven swing; even a "PR-then-data" one-two punch could squeeze shorts.</li>
<li>Risk management: both names are clinical-stage — size positions modestly, use stops, and consider call-spreads to bound downside.</li>
</ol>
<hr class="wp-block-separator has-alpha-channel-opacity" />
Bottom line: Monday's calendar lines up two asymmetric biotech shots: If Sana's six-month data look anything like the first patient's, endocrinologists will be talking — and buying — before lunch. If Lineage's big-pharma partner steps back into the headlines, we could see the May-style pop all over again.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Our positions in both stocks</h3>
Portfolio Armor Substack subscribers and I are long SANA and LCTX via options. I wrote about SANA <a href="https://www.benzinga.com/general/biotech/25/05/45498697/the-end-of-the-diabetes-industry-this-small-cap-could-upend-the-business-models-of-pharma-giants">here</a>.
<figure class="wp-block-image size-full"><a href="https://portfolioarmor.substack.com/p/the-end-of-the-diabetes-industry"><img loading="lazy" decoding="async" width="828" height="812" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050427/SANA.jpg" alt="" class="wp-image-14724" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050427/SANA.jpg 828w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050427/SANA-300x294.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050427/SANA-768x753.jpg 768w" sizes="(max-width: 828px) 100vw, 828px" /></a></figure>
And I first wrote about LCTX <a href="https://portfolioarmor.substack.com/p/trade-alert-biotech-lotto-ticket">last Friday</a>. 
<figure class="wp-block-image size-full"><a href="https://portfolioarmor.substack.com/p/trade-alert-biotech-lotto-ticket"><img loading="lazy" decoding="async" width="833" height="733" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050717/LCTX.jpg" alt="" class="wp-image-14725" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050717/LCTX.jpg 833w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050717/LCTX-300x264.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050717/LCTX-768x676.jpg 768w" sizes="(max-width: 833px) 100vw, 833px" /></a></figure>
We plan on selling half of our positions into a strong upward move to lock in profits. 
If you would like a heads up when we place our next trade, feel free to subscribe to the Portfolio Armor Substack below. 
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050929/Widget-2-1.jpg" alt="" class="wp-image-14726" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050929/Widget-2-1.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050929/Widget-2-1-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>
And if you want to limit your downside risk, in light of the conflict in the Mideast, consider <a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">the Portfolio Armor iPhone app</a> or <a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">website</a>. Both will help you scan for the optimal hedge given your risk tolerance and time frame. 
<figure class="wp-block-image aligncenter size-large"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23051320/PA-JPEG-1-2-1024x683.jpeg" alt="" class="wp-image-14727" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23051320/PA-JPEG-1-2-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23051320/PA-JPEG-1-2-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23051320/PA-JPEG-1-2-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23051320/PA-JPEG-1-2.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>

Biotech

Long Ideas

Options

Opinion

Trading Ideas

LCTX

RHHBY

SANA

Two Biotech Stocks Poised For Big Moves On Monday

CRCL: 10% &#x7C; <a href="https://www.benzinga.com//node/46048835">Fiserv Plans To Launch Fiserv Digital Asset Platform, Including New Stablecoin FIUSD; FIUSD Expects To Use Stablecoin Infrastructure From Paxos And Circle Internet Group</a>
&nbsp;
TSLA: 1.75% &#x7C; <a href="https://www.benzinga.com//node/46048103">Tesla's Robotaxi Rollout Sparks Expansion Buzz: Elon Musk's Company Says FSD 'Can Be Deployed Anywhere' After Austin Launch</a>
&nbsp;
SQNS: 64% &#x7C; <a href="https://www.benzinga.com//node/46048013">Sequans Unveils $384M Strategic Investment To Launch Bitcoin Treasury Initiative While Advancing 5G And IoT Core Mission</a>

Movers

CRCL

SQNS

TSLA

Market-Moving News for June 23rd

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced new data from an indirect treatment comparison (ITC) that showed consistent and sustained disease control with IMAAVY&#x2122; (nipocalimab-aahu) versus other approved FcRn blockers in adults with generalized myasthenia gravis (gMG). These data, featured at the European Academy of Neurology (EAN) 2025 Congress in Helsinki, Finland, are among the 11 abstracts Johnson &amp; Johnson&nbsp;is presenting.
&nbsp;
Based on the ITC, which included the pivotal Phase 3 Vivacity-MG3 study data, IMAAVY showed comparable onset of symptom relief at Week 1 and showed consistent and sustained disease control with greater or statistically significant improvement of MG-ADLa scores versus the published Phase 3 data of other marketed FcRn blockers at several timepoints up to 24 weeksb of treatment.1 Results were consistent across multiple ITC methodsc.
<ul>
<li>Population-adjusted&nbsp;ITCs without a common control exhibited significantly greater mean improvements in MG-ADL scores favoring IMAAVY over other FcRn blockers, at Weeks 8-24d versus one comparator and at Weeks 10-14d versus another comparator.1</li>
<li>In placebo-adjusted&nbsp;ITCs, IMAAVY was associated with numerically greater efficacy versus one treatment comparator at Weeks 8e and 18-24e and versus another at Weeks 10-14e, with statistical significance at Weeks 10f and 12f</li>
</ul>

Johnson & Johnson Reports Data Showing IMAAVY Controls Myasthenia Gravis Symptoms Better Than Rivals

Baird analyst Rob Oliver downgrades Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) from Outperform to Neutral and raises the price target from $22 to $25.

Downgrades

BASE

Baird Downgrades Couchbase to Neutral, Raises Price Target to $25

CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update related to its Large Dialysis Organization (LDO) customer and planned implementation in the second half of 2025.
CorMedix's LDO customer has commenced ordering and will begin the implementation of DefenCath in its patients. Implementation will initially target at least 50% more patients than previously communicated, with the opportunity for further expansion. In connection with this expanded utilization, CorMedix has amended its existing agreement with the LDO customer to reflect the anticipated increased use of product. CorMedix expects a modest revenue contribution in June, with growth expected over the back half of 2025.
As a result of this new customer implementation and other positive business developments, CorMedix is increasing its second quarter net sales guidance from the previously communicated $31mm to a range of $35mm to $40mm.
"I am excited to announce that our LDO customer is moving forward with the implementation of DefenCath. Their implementation of our product will provide access to DefenCath for thousands of adult patients at risk for catheter related bloodstream infections," says CorMedix CEO, Joseph Todisco. "CorMedix remains committed to our goal of ensuring broad access to this important infection reduction mechanism."

Guidance

CRMD

CorMedix Announces It Is Updating Its Q2 Net Sales Guidance From $31M To A Range Of $35M To $40M

Tidewater Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDW#NYSE">TDW</a>) ("Tidewater" or "the Company") today announced that it has commenced a private offering (the "Offering") of $650 million in aggregate principal amount of unsecured senior notes due 2030 (the "2030 Notes"). The Company expects to use the net proceeds from the Offering, together with cash on hand, (i) to repay in full the Company's existing senior secured term loan, (ii) to fund the redemption (the "Redemption") of both the Company's outstanding 8.50% Senior Secured Bonds due 2026 (the "2026 Bonds") and its outstanding 10.375% Senior Unsecured Bonds due 2028 (the "2028 Bonds") and (iii) to pay the premiums, accrued interest, fees and expenses related to the term loan payoff, Redemption and the issuance of the 2030 Notes. The 2030 Notes will be senior unsecured obligations of the Company and will be guaranteed on a senior unsecured basis by certain of the Company's U.S. subsidiaries.

Tidewater Commences Private Offering Of $650M In Aggregate Principal Amount Of Unsecured Senior Notes Due 2030

Fractyl&nbsp;Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Diabetes Association's (ADA) 85th Scientific Sessions. The abstract, titled "Single-Dose GLP-1-Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat Fed Mice," demonstrated that a single dose of Rejuva was well-tolerated in healthy mice, and prevented weight gain and hyperglycemia following a switch to a high-fat diet.
These findings further validate Rejuva's potential as a one-time, durable therapy with strong activity in obesity and diabetes and a favorable toxicity profile across multiple preclinical models. Importantly, these data highlight Rejuva's distinct mechanism of action, setting it apart from systemic GLP-1 receptor agonists. The Smart GLP-1 design of Rejuva enables nutrient-responsive secretion, exerting no physiologic effect under healthy metabolic conditions and only activating in the presence of metabolic stress. This targeted activity, which mimics the body's endogenous GLP-1 physiology, highlights the potential for Rejuva to offer superior potency and tolerability.

Fractyl Shares Preclinical Data on GLP-1 Gene Therapy for Obesity and Diabetes at ADA Meeting

Bank-friendly coin will allow access to digital assets through a simple, secure, and scalable platform
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fiserv.com%2F&amp;esheet=54280593&amp;newsitemid=20250623052523&amp;lan=en-US&amp;anchor=Fiserv%2C+Inc.&amp;index=1&amp;md5=5ea1ca30c1688fb83860bbb525b6c378">Fiserv, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>), a leading global provider of payments and financial services technology, today announced plans to launch a new Fiserv digital asset platform, including a new stablecoin (FIUSD) that will be added to Fiserv's existing banking and payments infrastructure by the end of the year.
FIUSD expects to use stablecoin infrastructure from Paxos and Circle Internet Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) – with the intention of making it interoperable with several leading stablecoins, and it will be available to Fiserv clients via Solana, one of the most trusted and used blockchains for stablecoins. In addition, the company is exploring the use of deposit tokens to maintain the benefits of stablecoins in a more capital-friendly structure for banks. Fiserv is active in discussions with other potential partners to further expand use cases for stablecoins and tokenized deposits, both in the United States and internationally.

Fiserv Plans To Launch Fiserv Digital Asset Platform, Including New Stablecoin FIUSD; FIUSD Expects To Use Stablecoin Infrastructure From Paxos And Circle Internet Group

Quanterix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration by the Ministry of Food and Drug Safety (MFDS) in South Korea through its regional distribution partner, HS Biosystems.
The continued expansion of the industry-leading <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.quanterix.com%2Fsimoa-technology%2F&amp;esheet=54280095&amp;newsitemid=20250623801054&amp;lan=en-US&amp;anchor=Simoa%26%23174%3B+technology+platform&amp;index=1&amp;md5=9a25b4c4fe77531fb51744f4ecaffb72">Simoa&#xAE; technology platform</a> into global markets demonstrates a key milestone in broadening validation of biomarker-based testing and providing clinicians with minimally invasive tools that can help enhance diagnostic accuracy and improve accessibility. Through its unparalleled sensitivity and multi-marker testing capability, the Simoa platform delivers ultrasensitive biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ) of traditional measurement platforms.

Government

Regulations

QTRX

Quanterix's Ultra-Sensitive Blood Test Platform Wins Medical Device Approval in South Korea

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and maintains $550 price target.

Reiteration

VRTX

HC Wainwright & Co. Reiterates Buy on Vertex Pharmaceuticals, Maintains $550 Price Target

JP Morgan analyst Daniel Politzer initiates coverage on Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) with a Neutral rating and announces Price Target of $284.

JP Morgan Initiates Coverage On Marriott International with Neutral Rating, Announces Price Target of $284

NETCLASS Technology INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>, the "Company" or "NetClass"))), a leading B2B smart education IT solutions provider with offices in Shanghai, Hong Kong, Singapore and Tokyo, is pleased to announce that it signed a Framework Agreement for Cooperation with Nanyang Institute of Social Sciences Ptd. Ltd. ("Nanyang Institute of Social Sciences"), a private higher education institution registered with Singapore's Ministry of Education, to mark the beginning of a new chapter in AI-powered education.
Through this partnership, NetClass will leverage its robust data and AI capabilities to enhance course delivery and improve teaching outcomes at Nanyang Institute of Social Sciences. In return, Nanyang Institute will draw on its strong local network and academic expertise to support NetClass's expansion in the Singapore market. Together, the two institutions aim to explore cutting-edge applications of digital technology in education and drive innovation in teaching models.
NetClass's online learning platform and AI-powered teaching assistant system have been widely recognized for their effectiveness and innovation. Building on this solid foundation, both parties plan to co-develop a smart digital learning platform focused on social and management sciences, designed to serve students worldwide. The platform will integrate intelligent systems for teaching, learning, and assessment to deliver more efficient education experiences.
This partnership will follow a phased approach, with both parties continuously exploring and refining the collaboration. At a future stage, NetClass and Nanyang Institute of Social Sciences will also consider equity-level cooperation to strengthen and scale their joint efforts, aiming to create a new paradigm in educational technology partnerships.
"The partnership represents a significant step forward in executing our global expansion strategy and strengthening our presence in Southeast Asia, one of the world's most dynamic education markets," said Dr. Jianbiao Dai, Chairman and Chief Executive Officer of NetClass. "By collaborating with Nanyang Institute of Social Sciences, NetClass gains valuable access to local market insights, academic networks, and regional credibility, accelerating our path to growth and long-term profitability. The initiative also aligns with NetClass's broader mission to build a globally scalable AI-powered education ecosystem, and diversify our business model across markets and verticals."

Contracts

NTCL

Netclass Technology Announces That It Signed A Framework Agreement For A Partnership With Nanyang Institute Of Social Sciences Ptd To Forward AI-Powered Education

Baird analyst David Manthey downgrades GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) from Outperform to Neutral and raises the price target from $93 to $95.

Baird Downgrades GMS to Neutral, Raises Price Target to $95

(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVLA#NASDAQ">PVLA</a>) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration&nbsp;(FDA)-approved therapies, today announced the successful completion of SELVA, a Phase 3 trial of QTORIN&#x2122; 3.9% rapamycin anhydrous gel (QTORIN&#x2122; rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs). The Phase 3 trial enrolled 51 subjects, exceeding the original target of 40 subjects by over 25%.
Top-line results from SELVA are expected in the first quarter of 2026, with a New Drug Application submission planned for the second half of 2026.

PVLA

Palvella Completes Enrollment In Phase 3 SELVA Trial Of QTORIN Rapamycin For Microcystic Lymphatic Malformations, Exceeding Target Of 40 Subjects By Over 25%

Press Releases

Shipping: State of Play & What Lies Ahead

International Seaways to Announce Fourth Quarter and Full Year 2024 Results on February 27, 2025

Industry Leaders Presenting at Capital Link's 19th Annual International Shipping Forum - Monday March 31, 2025, New York City

International Seaways Reports Fourth Quarter and Full Year 2024 Results

Gas & Tankers Shipping Industry Leaders Presenting at Capital Link's 19th Annual International Shipping Forum - Monday, March 31, 2025, New York City

REMINDER: Gas & Tankers Shipping Industry Leaders Presenting at Capital Link's 19th Annual International Shipping Forum - Monday, March 31, 2025, New York City

International Seaways to Announce First Quarter 2025 Results on May 8, 2025

Economics

Insights from Industry Leaders: Capital Link's Quarterly Shipping Report – Q1 2025

International Seaways Reports First Quarter 2025 Results

International Seaways and V. Partner to Launch Female Cadet Program

BWLP

CCEC

CDLR

CLCO

DMCOF

EDRY

ESEA

FLNG

GOGL

HAFN

INSW

NVGS

PANL

SBLK

SHIP

STNG

SVCCU

USEA

BW LPG

CrossAmerica Partners LP Common Units representing limited partner interests

CrossAmerica Partners

CMB.Tech

DHT Holdings

Delek Logistics Partners, L.P. Common Units representing Limited Partner Interests

Delek Logistics Partners

Okeanis Eco Tankers

Excelerate Energy, Inc. Class A Common Stock

Excelerate Energy

Flex LNG

Frontline

Genesis Energy

Golar LNG

Global Partners LP Common Units representing Limited Partner Interests

Global Partners

Hafnia

Hess Midstream LP Class A Representing Limited Partner Interests

Hess Midstream

Kinetik Holdings Inc. Class A Common Stock

Kinetik Holdings

Dorian LPG

NextDecade

Navigator Holdings Ltd. Ordinary Shares (Marshall Islands)

Navigator Holdings

Plains GP Holdings, L.P. - Class A Shares representing limited partner interests

Plains GP Holdings

SFL Corp

Scorpio Tankers

Transportadora de Gas del Sur SA TGS Common Stock

Transportadora de Gas

Teekay Tankers

TORM

Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share)

Comments

International Seaways

Interés en corto

International Seaways (NYSE:INSW) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL